ALKERMES | ALKS - 债务利息支出

金融业

USD

USD 2.49B

现金及等价物

USD 388.57M

USD 46.21M

USD 1.93B

USD 543.44M

USD 71.6M

股息收益率

0

USD -10.95M

USD 100.31M

1.8K

EPS每股收益

USD 0.29

股本和储备

USD 1.82B

USD 338.34M

债务利息支出

USD 12.28M

USD 11.94M

USD 285.82M

USD 4.53B

USD 49.34M

USD 326.44M

USD -10.95M

普通股股本

USD 165.61M

19.54

USD 100.74M

USD 384.5M

销售和管理费用

USD 187.2M

USD 196.63M

贸易债权人

USD 107.95M

应收帐款人

USD 334.03M

	债务利息支出	更改		日
AbbVie	USD 740M		40M	2025-06
Acadia Pharmaceuticals	USD 0		4.12M	2024-09
ALKERMES	USD 12.28M		7.63M	2025-12
Amgen	USD 653M		32M	2025-12
Biogen	USD 72.6M		12.6M	2025-06
BioMarin Pharmaceutical	USD 2.78M		199K	2025-12
Bristol-Myers Squibb	USD 432M		48M	2025-12
Coherus Biosciences	USD 2.15M		3.2M	2025-03
Eli Lilly	USD 114.7M		134.3M	2025-09
Gilead Sciences	USD 255M		1000K	2025-12
Heron Therapeutics	USD 600K		100K	2024-12
Ionis Pharmaceuticals	USD 18M		0	2025-12
J&J	USD 18M		290M	2025-09
Merck	USD 412M		85M	2025-12
Minerva Neurosciences	USD 2.31M		60K	2024-06
Nektar Therapeutics	USD 6.02M		420K	2024-09
Neurocrine Biosciences	USD 1.1M		0	2024-03
Otsuka Holdings	JPY 2.21B		866M	2025-12
Ovoca Bio	EUR 7K		6K	2022-06
Pfizer	USD 711M		59M	2025-12
Regeneron Pharmaceuticals	USD 12.2M		7.1M	2025-12
Vertex Pharmaceuticals	USD 3.3M		0	2025-12